VIVEbiotech, a leading lentiviral vector Contract Development and Manufacturing Organization (CDMO), announces a growth equity investment from Ampersand Capital Partners (“Ampersand”), a private equity firm specializing in the life sciences and healthcare sectors. VIVEbiotech provides process development, manufacturing and analytical testing for leading biopharmaceutical companies engaged in gene therapy and cell therapy projects. With a specific focus on lentiviral vector production, the Company operates a state-of-the-art, 3,000 sq. m. (32,000 sq. ft.) GMP-compliant facility in San Sebastián, Gipuzkoa, Spain.
Read the full article: VIVEbiotech Secures Growth Investment from Ampersand Capital Partners to Expand Lentiviral Vector Development and Manufacturing Capabilities //
Source: https://www.prnewswire.com/news-releases/vivebiotech-secures-growth-investment-from-ampersand-capital-partners-to-expand-lentiviral-vector-development-and-manufacturing-capabilities-302321813.html